Medication Reminders Are a Trojan Horse for Pharma Marketing

01 /The Concept

Elfie bills itself as the world's first free app that rewards users for actively managing their own health.

The app covers three layers of health management. At its core, it's a health metrics journal – users log blood pressure, blood sugar, cholesterol, and similar indicators either manually or through connected wearables. Layered on top is goal-setting for health outcomes: reducing stress, losing weight, quitting smoking, cutting calorie intake. And it doubles as a medication reminder, backed by a catalog of 4 million medications and a marketplace of over 30,000 pharmacies where users can order directly.

The clever part: Elfie's AI assistant starts nudging users when they stop logging medication intake or stop reordering – specifically for chronic condition medications that need to be taken indefinitely. This matters because most patients stop taking their medications within a year of diagnosis, once their condition stabilizes. What follows – predictably – is a relapse, often more severe than the original episode.

For every health-positive action – logging a metric, completing a step in a habit program, taking a medication – the app awards a digital coin. Those coins can be redeemed for medications, health products, or medical services ordered through the app.

Since launching in 2021, Elfie has distributed more than 3 billion coins. The app now has over 700,000 users across multiple countries, with dedicated market launches in Vietnam, Brazil, Turkey, and Egypt.

Those country launches are about more than connecting local pharmacies. Elfie actively works with employers and healthcare providers on two separate tracks.

For employers, the pitch is straightforward: enroll your workforce and reduce sick days. Elfie helps companies set health targets, supports their rollout through the app, and integrates with local telemedicine providers.

In healthcare settings, Elfie incentivizes staff – not just physicians, but nurses and front-desk personnel too – for connecting patients to the platform. With doctors, the goal is building a habit of asking patients: "Show me your Elfie." That unlocks a continuous health log, far more reliable than asking patients to recall their history on the spot.

Elfie had previously raised $4 million (disclosed in early 2023). It has now closed a new round of $12 million.

02 /Why It Matters

Elfie isn't quite the "world's first" in this space, as it claims. Sempre Health ([covered here](/review/napominalka-na-45-millionov-dollarov)) operates on a very similar concept – though with a different mechanic. Users who consistently take and reorder their medications through the app earn escalating discounts on future purchases. Sempre has raised $45.5 million to date.

Both apps are targeting the same audience: people managing chronic conditions who need to take medication indefinitely to avoid deterioration.

The scale of that market is staggering. Approximately 3.4 billion people worldwide live with chronic conditions – hypertension, diabetes, high cholesterol, dyslipidemia, cancer, chronic lung disease, cardiovascular disease, and so on. That's roughly one in every two people on Earth. In the US alone, 171 million people are expected to be living with a chronic condition by 2030.

For pharmaceutical companies, this population represents their highest-LTV customer segment – patients who, if adherent, will be purchasing the same medications for life. Which makes the adherence problem a serious commercial issue: if most patients quit within a year of diagnosis, pharma companies lose that lifetime value fast.

Competition in pharma is fierce too. For any given chronic condition, there are usually multiple competing drugs from multiple manufacturers. That's one reason pharma invests so heavily in advertising. In the US, prescription drug ads account for 85% of all health-related internet advertising – and the category is growing. Pharma digital ad spend in the US was around $15 billion in 2022 and is expected to reach nearly $22 billion in 2026.

That growth is also pushing pharma to find better-performing alternatives to straightforward display ads. Platforms like Elfie and Sempre Health are attractive because they reach patients at exactly the moment of medication decisions and create a direct purchase pathway.

Parallel to this, there's interest in influencing prescribing physicians through new channels. VuMedi ([covered here](/review/prostoj-sposob-otkusit-kusochek-ogromnyh-bjudzhetov)) – a professional video platform purpose-built for doctors, essentially a YouTube for medical education – illustrates the trend. Founded in 2009, it raised only about $2 million over its entire history before pulling in $80 million in a single round this past May.

Elfie's trajectory rhymes with that: $5 million raised across its first several years, then a $12 million round. The pattern suggests that as traditional pharma ad channels become saturated and less effective, the industry is finally investing meaningfully in alternative channels.

03 /Opportunities

The moment to act on is the sudden, accelerating shift in pharma marketing budgets toward non-traditional channels. It's been building for a while – now it's breaking through.

That creates a window to build your own alternative marketing channel in this space – whether by following the models described here or by inventing a new mechanic entirely.

One note on the ethics: apps like Elfie and Sempre Health aren't purely a pharma revenue play. They genuinely help people maintain their health and save money on medications. Everyone wins – patients, pharma, and the platforms themselves.

And with roughly half the world's population living with at least one chronic condition, the addressable market is large enough to build a billion-dollar company.